DCF Valuation

POMDOCTOR LIMITED American Depositary Shares (POM) DCF Valuation — Is POM undervalued?

The estimated DCF fair value of one POMDOCTOR LIMITED American Depositary Shares (POM) share is $17.78. Compared to the current market price of $0.70, the stock is undervalued by 2438.7%.

DCF fair value

$17.78

Market price

$0.70

Upside / downside

+2438.7%

Run the full interactive DCF model →

Prefer the inverse question? See what growth rate the market is pricing into POM

POMDOCTOR LIMITED American Depositary Shares (POM) DCF valuation FAQ

What is the DCF fair value of POMDOCTOR LIMITED American Depositary Shares (POM)?

The discounted-cash-flow model estimates the intrinsic fair value of one POMDOCTOR LIMITED American Depositary Shares (POM) share at $17.78, based on a 10-year projection of its cash flows converging to Damodaran industry averages.

Is POMDOCTOR LIMITED American Depositary Shares (POM) overvalued or undervalued?

Against the current market price of $0.70, the DCF fair value of $17.78 implies POM is undervalued by 2438.7%.

How is the POM DCF value calculated?

It is a 10-year discounted-cash-flow estimate built from POMDOCTOR LIMITED American Depositary Shares's reported fundamentals, with terminal assumptions anchored to Damodaran NYU industry datasets. The market price refreshes daily; the DCF fair value updates when POMDOCTOR LIMITED American Depositary Shares files a new quarterly or annual report.

How this POM valuation is built

The model projects ten years of POMDOCTOR LIMITED American Depositary Shares's free cash flow to the firm and discounts each year at its own cost of capital. Rather than assuming today's growth and margins persist forever, a moat-scoring step — weighing POMDOCTOR LIMITED American Depositary Shares's ROIC-versus-WACC spread, gross-margin trend, and reinvestment efficiency — decides how many years the business holds its edge before its economics mean-revert toward the Damodaran NYU benchmarks for its industry.

WACC is rebuilt each year from an unlevered-then-relevered beta and the company's evolving capital structure; terminal value uses the Gordon growth model with a reinvestment rate tied to the return earned on new capital (goodwill stripped out to reflect operating efficiency). Every assumption — growth, margins, tax, leverage, convergence timing — is editable, and running the full interactive model adds a 10,000-draw Monte Carlo simulation and WACC-versus-terminal-growth sensitivity heatmaps.

The market price refreshes daily; the DCF fair value updates when POMDOCTOR LIMITED American Depositary Shares files a new quarterly or annual report. For educational/informational purposes only — not investment advice. Last updated 2026-08-06.